Positive Expression of Paired Box 5 (Pax5) was Associated with Age,
Tumor Location, and Tumor Size of Patients with Gastrointestinal Neuroendocrine
Tumors (NETs)

Ting      Zhang; Fangfang      Hong; Haibo      Wu

doi:10.2174/1570180819666220922103528

Abstract

Background: Neuroendocrine tumors (NETs) can occur in most human epithelial organs, however, there are few studies on digestive system NETs.

Aims: The study aims to analyze Pax5 expression in digestive tract NETs and discuss its diagnostic significance.

Methods: This study included 64 cases of NETs diagnosed from 2019 to 2020. Expressions of paired box 5 (Pax5), CD56, synaptophysin (Syn), and chromogranin (CgA) were detected using the immunohistochemical assay. Clinicopathological parameters, including tumor location, histological classification, depth of infiltration, tumor diameter, lymph node metastasis, vascular tumor thrombus, and nerve invasion, were determined in Pax5 positive and negative patients. Spearman correlation analysis was performed to analyze the correlation between Pax5 and CD56, Syn, and CgA.

Results: The positive rate of Pax5 expression in patients with NETs was 46.9% (30/64). There were more patients ≥60 years illustrating positive expression of Pax5 compared to those patients <60 years (χ²=8.438, P=0.004). There were significant differences in histological classification between Pax5 positive expression patients and Pax5 negative expression patients (χ²=17.639, P=0.011). Significant Pax5 positive expression patients demonstrated tumor size ≥3 cm, compared to Pax5 negative expression patients (χ²=6.764, P=0.009). Therefore, positive Pax5 expression was related to age, histological classification, and tumor size of NETs patients. Pax5 expression in digestive system NETs was not correlated with CD56 (χ²=0.233, r=0.024, P=0.853), Syn (χ²=0.635, r=0.047, P=0.715), CgA (χ²=2.346, r=0.170, P=0.179).

Conclusion: Positive expression of Pax5 was related to age, tumor location, and tumor size of NETs patients. Pax5 can be used in combination with common immune markers (CD56/Syn/CgA) and can improve the diagnostic accuracy of digestive system NETs.

Keywords: paired box 5 (Pax5), neuroendocrine tumors (NETs), digestive system, clinicopathological characteristics, immune markers, neuroendocrine carcinoma (NEC)

« Previous Next »

Graphical Abstract

[1]
Dong, Y.; Li, Y.; Liu, R.; Li, Y.; Zhang, H.; Liu, H.; Chen, J. Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA. Syn and Napsin A. Oncol. Lett.,  2020, 19(3), 2223-2230.
 [http://dx.doi.org/10.3892/ol.2020.11336] [PMID:  32194720]

[2]
Eren, B.; Guzey, F.K.; Gulec, I.; Tufan, A. Metastatic gallbladder carcinoma in meningioma: A case report. Turk Neurosurg.,  2019, 29(2), 297-299.
 [PMID:  28731197]

[3]
Tirosh, A.; Kebebew, E. The utility of68 Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol.,  2018, 14(2), 111-122.
 [http://dx.doi.org/10.2217/fon-2017-0393] [PMID:  29072093]

[4]
Oronsky, B.; Ma, P.C.; Morgensztern, D.; Carter, C.A. Nothing But NET: A review of neuroendocrine tumors and carcinomas. Neoplasia,  2017, 19(12), 991-1002.
 [http://dx.doi.org/10.1016/j.neo.2017.09.002] [PMID:  29091800]

[5]
Dasari, A.; Shen, C.; Halperin, D.; Zhao, B.; Zhou, S.; Xu, Y.; Shih, T.; Yao, J.C. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol.,  2017, 3(10), 1335-1342.
 [http://dx.doi.org/10.1001/jamaoncol.2017.0589] [PMID:  28448665]

[6]
Ahmed, M. Gastrointestinal neuroendocrine tumors in 2020. World J. Gastrointest. Oncol.,  2020, 12(8), 791-807.
 [http://dx.doi.org/10.4251/wjgo.v12.i8.791] [PMID:  32879660]

[7]
Calderón, L.; Schindler, K.; Malin, S.G.; Schebesta, A.; Sun, Q.; Schwickert, T.; Alberti, C.; Fischer, M.; Jaritz, M.; Tagoh, H.; Ebert, A.; Minnich, M.; Liston, A.; Cochella, L.; Busslinger, M. Pax5 regulates B cell immunity by promoting PI3K signaling via PTEN down-regulation. Sci. Immunol.,  2021, 6(61), eabg5003.
 [http://dx.doi.org/10.1126/sciimmunol.abg5003] [PMID:  34301800]

[8]
Cobaleda, C.; Schebesta, A.; Delogu, A.; Busslinger, M. Pax5: The guardian of B cell identity and function. Nat. Immunol.,  2007, 8(5), 463-470.
 [http://dx.doi.org/10.1038/ni1454] [PMID:  17440452]

[9]
Revilla-i-Domingo, R.; Bilic, I.; Vilagos, B.; Tagoh, H.; Ebert, A.; Tamir, I.M.; Smeenk, L.; Trupke, J.; Sommer, A.; Jaritz, M.; Busslinger, M. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J.,  2012, 31(14), 3130-3146.
 [http://dx.doi.org/10.1038/emboj.2012.155] [PMID:  22669466]

[10]
Medvedovic, J.; Ebert, A.; Tagoh, H.; Busslinger, M. Pax5: A master regulator of B cell development and leukemogenesis. Adv. Immunol.,  2011, 111, 179-206.
 [http://dx.doi.org/10.1016/B978-0-12-385991-4.00005-2] [PMID:  21970955]

[11]
Xiao, G.; Chan, L.N.; Klemm, L.; Braas, D.; Chen, Z.; Geng, H.; Zhang, Q.C.; Aghajanirefah, A.; Cosgun, K.N.; Sadras, T.; Lee, J.; Mirzapoiazova, T.; Salgia, R.; Ernst, T.; Hochhaus, A.; Jumaa, H.; Jiang, X.; Weinstock, D.M.; Graeber, T.G.; Müschen, M. B-Cell-specific diversion of glucose carbon utilization reveals a unique vulnerability in B cell malignancies. Cell,  2018, 173(2), 470-484.e18.
 [http://dx.doi.org/10.1016/j.cell.2018.02.048] [PMID:  29551267]

[12]
Czapiewski, P.; Majewska, H.; Kutzner, H.; Kazakov, D.; Renkielska, A.; Biernat, W. TTF-1 and PAX5 are frequently expressed in combined merkel cell carcinoma. Am. J. Dermatopathol.,  2016, 38(7), 513-516.
 [http://dx.doi.org/10.1097/DAD.0000000000000464] [PMID:  27322785]

[13]
Kanteti, R.; Nallasura, V.; Loganathan, S.; Tretiakova, M.; Kroll, T.; Krishnaswamy, S.; Faoro, L.; Cagle, P.; Husain, A.N.; Vokes, E.E.; Lang, D.; Salgia, R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab. Invest.,  2009, 89(3), 301-314.
 [http://dx.doi.org/10.1038/labinvest.2008.168] [PMID:  19139719]

[14]
Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A. The 2019 WHO classification of tumours of the digestive system. Histopathology,  2020, 76(2), 182-188.
 [http://dx.doi.org/10.1111/his.13975] [PMID:  31433515]

[15]
Lee, I.S.; Choi, W.H.; Kim, J.Y.; Jeong, J.Y.; Kim, M.J.; Nam, J.H.; Kim, J.H.; Seo, S.B.; Pak, J.H. Transcriptional regulation of the murine 1-cys peroxiredoxin gene by the B cell-specific activator protein, Pax5. J. Cell. Biochem.,  2008, 104(2), 465-476.
 [http://dx.doi.org/10.1002/jcb.21638] [PMID:  18172866]

[16]
Yuan, X.L.; Zhang, B.; Jiang, L.M.; Shen, L.S. Effect of pax5 gene blocked by RNAi on biological characteristics of B cell malignant lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi,  2008, 16(4), 799-803.
 [PMID:  18718064]

[17]
Ainechi, S.; Mann, S.A.; Lin, J.; Patil, D.; Sheehan, C.E.; Yang, Z.; Zuo, C.; Lee, H. Paired Box 5 (PAX5) expression in poorly differentiated neuroendocrine carcinoma of the gastrointestinal and pancreatobiliary tract: Diagnostic and potentially therapeutic implications. Appl. Immunohistochem. Mol. Morphol.,  2018, 26(8), 545-551.
 [http://dx.doi.org/10.1097/PAI.0000000000000473] [PMID:  27941564]

[18]
Souche, R.; Coignac, A.; Dupuy, M.; Bertrand, M.; Raingeart, I.; Guiu, B.; Herrero, A.; Panaro, F.; Obled, S.; Portales, F.; Riviere, B.; Ramos, J.; Borie, F.; Quenet, F.; Colombo, P.E.; Prudhomme, M.; Assenat, E.; Fabre, J.M. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients. Clin. Res. Hepatol. Gastroenterol.,  2020, 44(3), 286-294.
 [http://dx.doi.org/10.1016/j.clinre.2019.08.010] [PMID:  31543336]

[19]
Tang, L.H.; Untch, B.R.; Reidy, D.L.; O’Reilly, E.; Dhall, D.; Jih, L.; Basturk, O.; Allen, P.J.; Klimstra, D.S. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer Res.,  2016, 22(4), 1011-1017.
 [http://dx.doi.org/10.1158/1078-0432.CCR-15-0548] [PMID:  26482044]

[20]
Desai, G.S.; Pande, P.; Shah, R.C.; Jagannath, P. Dilemmas in diagnosis and management of gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms: First single-centre report from India. J. Gastrointest. Cancer,  2020, 51(1), 102-108.
 [http://dx.doi.org/10.1007/s12029-019-00213-0] [PMID:  30784017]

[21]
Kolin, D.L.; Duan, K.; Ngan, B.; Gerstle, J.T.; Krzyzanowska, M.K.; Somers, G.R.; Mete, O. Expanding the spectrum of colonic manifestations in tuberous sclerosis: L-Cell neuroendocrine tumor arising in the background of rectal PEComa. Endocr. Pathol.,  2018, 29(1), 21-26.
 [http://dx.doi.org/10.1007/s12022-017-9497-0] [PMID:  28733877]

[22]
Fu, Z.; Zuo, C.; Sheehan, C.E.; Patil, D.T.; Lin, J.; Yang, Z.; Lee, H. Novel finding of paired box 5 (PAX5) Cytoplasmic staining in well-differentiated rectal neuroendocrine tumors (Carcinoids) and its diagnostic and potentially prognostic utility. Appl. Immunohistochem. Mol. Morphol.,  2019, 27(6), 454-460.
 [http://dx.doi.org/10.1097/PAI.0000000000000635] [PMID:  29561272]

[23]
Inzani, F.; Santoro, A.; Angelico, G.; Feraco, A.; Spadola, S.; Arciuolo, D.; Valente, M.; Carlino, A.; Piermattei, A.; Scaglione, G.; Scambia, G.; Rindi, G.; Zannoni, G.F. Neuroendocrine carcinoma of the uterine cervix: A clinicopathologic and immunohistochemical study with focus on novel markers (Sst2–Sst5). Cancers (Basel),  2020, 12(5), 1211.
 [http://dx.doi.org/10.3390/cancers12051211] [PMID:  32408525]

[24]
Chen, P.P.; Ramalingam, P.; Alvarado-Cabrero, I.; Euscher, E.D.; Nagarajan, P.; Lawson, B.C.; Malpica, A. High-grade neuroendocrine carcinomas of the vulva. Am. J. Surg. Pathol.,  2021, 45(3), 304-316.
 [http://dx.doi.org/10.1097/PAS.0000000000001558] [PMID:  32826525]

Rights & Permissions Print Cite

Explore Articles

Open Access

Open Access Articles

DOI https://dx.doi.org/10.2174/1570180819666220922103528	Print ISSN 1570-1808
Publisher Name Bentham Science Publisher	Online ISSN 1875-628X

Letters in Drug Design & Discovery

Positive Expression of Paired Box 5 (Pax5) was Associated with Age, Tumor Location, and Tumor Size of Patients with Gastrointestinal Neuroendocrine Tumors (NETs)

Abstract Play Pause

Graphical Abstract

Abstract